Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
11 2021
Historique:
received: 15 09 2020
revised: 15 08 2020
accepted: 22 08 2020
pubmed: 17 9 2020
medline: 15 2 2022
entrez: 16 9 2020
Statut: ppublish

Résumé

To establish expert recommendations for the management of ocular sarcoidosis (OS). A question-based survey on the management of OS was circulated to international uveitis experts (members of the International Uveitis Study Group and the International Ocular Inflammation Society) electronically. Subsequently, a consensus workshop was conducted at the 7th International Workshop on Ocular Sarcoidosis (IWOS) in June 2019 in Sapporo, Japan as part of the Global Ocular Inflammation Workshops. Statements on the management of OS that were supported by a two-thirds majority of 10 international panel members of the workshop, after discussion and voting, were taken as consensus agreement. A total of 98 participants from 29 countries responded to the questionnaire survey. The subsequent consensus workshop established recommendations for the management of OS in five sections. The first section concerned evaluation and monitoring of inflammation. The second, third and fourth sections described ocular manifestations that were indications for treatment, and the management of anterior uveitis, intermediate uveitis and posterior uveitis. In the fifth section, the use of systemic corticosteroids and systemic immunosuppressive drugs were detailed. Recommendations for management of OS were formulated through an IWOS consensus workshop.

Identifiants

pubmed: 32933934
pii: bjophthalmol-2020-317354
doi: 10.1136/bjophthalmol-2020-317354
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1515-1519

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Hiroshi Takase (H)

Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Nisha R Acharya (NR)

Proctor Foundation, University of California San Francisco, San Francisco, CA, USA.

Kalpana Babu (K)

Prabha Eye Clinic and Research Centre, Vittala International Institute of Ophthalmology, Bangalore, India.

Bahram Bodaghi (B)

Department of Ophthalmology, IHU FOReSIGHT, Sorbonne-APHP, Paris, France.

Moncef Khairallah (M)

Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia.

Peter J McCluskey (PJ)

Save Sight Institute, Discipline of Clinical Ophthalmology and Eye Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.

Nattaporn Tesavibul (N)

Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Jennifer E Thorne (JE)

Division of Ocular Immunology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, BaltimoreMD, USA.

Ilknur Tugal-Tutkun (I)

Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

Joyce H Yamamoto (JH)

Department of Ophthalmology, Faculdade de Medicina LIM-33 FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

Narsing A Rao (NA)

USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.

Justine R Smith (JR)

Flinders University College of Medicine and Public Health, Adelaide, SA, Australia.

Manabu Mochizuki (M)

Department of Ophthalmology and Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan m.manabu.oph@tmd.ac.jp.
Miyata Eye Hospital, Miyakonojo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH